Latest News

Latest News

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

Weekly News Roundup | 16 November 2026

Weekly News Roundup | 16 November 2026

Life science news 16 November 2026: the FDA approved Sunharbo, which it calls the first factor XIa inhibitor for stroke prevention. Sunharbo is approved with antiplatelet therapy after a recent ischaemic stroke. Imfinzi with enfortumab vedotin gained approval in...

read more
Clinical Trial Results 13 November 2026

Clinical Trial Results 13 November 2026

Clinical trial results 13 November 2026: obesity and cardiovascular risk, sleep apnoea, hepatitis delta, hidradenitis suppurativa, triglycerides and peanut allergy. Boehringer Ingelheim’s survodutide met its cardiovascular non-inferiority endpoint in obesity. Eli...

read more
From GLP-1 Trial Results to the Follow-Up Visit

From GLP-1 Trial Results to the Follow-Up Visit

A patient returns for follow-up after starting a GLP-1 receptor agonist. Their weight is down, but nausea has made meals unpredictable, and their insurer has declined the next refill. The GLP-1 trial results that helped start the conversation are still relevant. The...

read more
Weekly News Roundup | 16 November 2026

Weekly News Roundup | 16 November 2026

Life science news 16 November 2026: the FDA approved Sunharbo, which it calls the first factor XIa inhibitor for stroke prevention. Sunharbo is approved with antiplatelet therapy after a recent ischaemic stroke. Imfinzi with enfortumab vedotin gained approval in...

read more
Clinical Trial Results 13 November 2026

Clinical Trial Results 13 November 2026

Clinical trial results 13 November 2026: obesity and cardiovascular risk, sleep apnoea, hepatitis delta, hidradenitis suppurativa, triglycerides and peanut allergy. Boehringer Ingelheim’s survodutide met its cardiovascular non-inferiority endpoint in obesity. Eli...

read more
From GLP-1 Trial Results to the Follow-Up Visit

From GLP-1 Trial Results to the Follow-Up Visit

A patient returns for follow-up after starting a GLP-1 receptor agonist. Their weight is down, but nausea has made meals unpredictable, and their insurer has declined the next refill. The GLP-1 trial results that helped start the conversation are still relevant. The...

read more

Featured Articles

DNA double helix beside a microscope, test tubes and a pipette over a petri dish, representing life science publishing

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

Longevity Science Is Advancing. Can Clinical Care Keep Up?

Longevity Science Is Advancing. Can Clinical Care Keep Up?

The search to live longer is not new, but we are no longer looking for a hypothetical fountain of youth. Over the past few decades, research into metabolic health, longevity biomarkers, and more has led to longevity breakthroughs that open up new possibilities for...

read more
Lilly vs Novo in 2026: How the Obesity Market Has Shifted

Lilly vs Novo in 2026: How the Obesity Market Has Shifted

Lilly vs Novo is the rivalry that defines obesity medicine, and 2026 has redrawn the balance between the two companies. Third-quarter results published on 29 October and 4 November show Eli Lilly growing at a scale few drugmakers have reached. Novo Nordisk, meanwhile,...

read more

Further News

Clinical Trial Results 13 November 2026

Clinical trial results 13 November 2026: obesity and cardiovascular risk, sleep apnoea, hepatitis delta, hidradenitis suppurativa, triglycerides and peanut allergy. Boehringer Ingelheim’s survodutide met its cardiovascular non-inferiority endpoint in obesity. Eli...

NICE Cost-Effectiveness Threshold: What Has Changed Six Months On?

The NICE cost-effectiveness threshold rose on 31 March 2026, the first increase in more than two decades. Six months on, early data suggest appraisal committees are using the wider range in full. Recommendation rates have risen, and fewer companies are walking away...

Risto-cel Approval: When Could Beam’s Sickle Cell Therapy Reach Patients?

Beam Therapeutics plans to file for US risto-cel approval as early as year-end 2026. Under the FDA’s published review goals, a decision would follow roughly eight to 12 months after submission. No FDA action date has been announced. The plan follows positive topline...

argenx Unnatural Products Deal: What Does $550 Million Upfront Buy?

The argenx Unnatural Products deal buys a macrocyclic peptide discovery platform and its Santa Cruz research team. It also brings a portfolio of therapeutic macrocycles, none of which the companies have named. argenx will pay $550 million upfront in cash. Up to $595...

Beyond the Magic Marker: What EEG Could Add to ADHD Assessment

The search for a single brainwave test for ADHD has largely failed. But that was always the wrong goal. The more useful question is whether EEG, used alongside clinical assessment, could add information that helps make ADHD assessment more accurate and treatment more...

From GLP-1 Trial Results to the Follow-Up Visit

A patient returns for follow-up after starting a GLP-1 receptor agonist. Their weight is down, but nausea has made meals unpredictable, and their insurer has declined the next refill. The GLP-1 trial results that helped start the conversation are still relevant. The...

Biotech IPO Tracker 2026: How This Year’s Listings Have Traded

Biotech IPO tracker last updated: 10 November 2026. Prices as of the 6 November 2026 close. After a lean 2025, this year has reopened the US market for biotech flotations. This biotech IPO tracker lists every US-listed drug developer that has priced an initial public...

Creative Biolabs Helps Improve Reproducibility Across iPSC Organoid Studies

As iPSC-derived organoids gain importance in disease modeling and drug discovery, Creative Biolabs highlights iPSC differentiation consistency, cell characterization, and application-specific validation to help researchers develop more reliable experimental models....

Factor XIa Inhibitor Approved: How Asundexian Compares With Milvexian

Bayer’s asundexian is the first factor XIa inhibitor approved by the FDA. What OCEANIC-STROKE shows and how it compares with milvexian.

    Longevity Science Is Advancing. Can Clinical Care Keep Up?

    The search to live longer is not new, but we are no longer looking for a hypothetical fountain of youth. Over the past few decades, research into metabolic health, longevity biomarkers, and more has led to longevity breakthroughs that open up new possibilities for...

    Three Grant Budget Rules That Quietly Cost Life Science SMEs Money

    Most biotech and medtech teams that lose grant money do not lose it by being ineligible. They lose it by putting a correct cost in the wrong line. The three grant budget rules below come up in almost every budget review: one from Horizon Europe, one from US federal...

    GLP-1 Medications List: Every Approved GLP-1 Receptor Agonist Compared (2026)

    Regulatory status checked on 11 November 2026. Seven molecules make up the approved GLP-1 class in the US, Europe and the UK. They differ in dosing, in whether they are injections or tablets, and in the conditions they treat. This GLP-1 medications list covers every...

    Want to Be Part of the Next Chapter in Life Sciences Media?

     

    LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

     

     

    Don’t wait for the media to pick up your story. Be the media.

    See More Articles

    Want to Be Part of the Next Chapter in Life Sciences Media?

     

    LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

     

     

    Don’t wait for the media to pick up your story. Be the media.